Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Pericay

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Medicina Clinica|August 2, 2001
[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations]C Pericay, O Díez, B Campos, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 23, 2016
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trialF Longo-Muñoz, G Argiles, J Tabernero, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 15, 2014
TTD consensus document on the diagnosis and management of exocrine pancreatic cancerM Benavides, A Abad, I Ales, et al.
International Journal of Colorectal Disease|December 14, 2017
Non-inferiority multicenter prospective randomized controlled study of rectal cancer T<sub>2</sub>-T<sub>3s</sub> (superficial) N<sub>0</sub>, M<sub>0</sub> undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME)X Serra-Aracil, C Pericay, T Golda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2011
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study)E Aranda, J L Manzano, F Rivera, et al.
Human Mutation|June 1, 2001
The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcriptA Vega, B Campos, B Bressac-De-Paillerets, et al.
Hematology (Amsterdam, Netherlands)|June 16, 2001
Bone Marrow Transplantation: Prognostic Factors of Peripheral Blood Stem Cell Mobilization with Cyclophosphamide and Filgrastim (r-metHuG-CSF): The CD34+ Cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements after High-Dose ChemotherapyC. Solá, P. Maroto, R. Salazar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry?R Font, J A Espinas, L Layos, et al.
Investigational New Drugs|October 1, 2013
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD studyM Martin-Richard, R Gallego, C Pericay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trialU B Patel, G Brown, I Machado, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Medicina Clinica|August 2, 2001
[Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations]C Pericay, O Díez, B Campos, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 23, 2016
Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trialF Longo-Muñoz, G Argiles, J Tabernero, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 15, 2014
TTD consensus document on the diagnosis and management of exocrine pancreatic cancerM Benavides, A Abad, I Ales, et al.
International Journal of Colorectal Disease|December 14, 2017
Non-inferiority multicenter prospective randomized controlled study of rectal cancer T<sub>2</sub>-T<sub>3s</sub> (superficial) N<sub>0</sub>, M<sub>0</sub> undergoing neoadjuvant treatment and local excision (TEM) vs total mesorectal excision (TME)X Serra-Aracil, C Pericay, T Golda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2011
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study)E Aranda, J L Manzano, F Rivera, et al.
Human Mutation|June 1, 2001
The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcriptA Vega, B Campos, B Bressac-De-Paillerets, et al.
Hematology (Amsterdam, Netherlands)|June 16, 2001
Bone Marrow Transplantation: Prognostic Factors of Peripheral Blood Stem Cell Mobilization with Cyclophosphamide and Filgrastim (r-metHuG-CSF): The CD34+ Cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements after High-Dose ChemotherapyC. Solá, P. Maroto, R. Salazar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry?R Font, J A Espinas, L Layos, et al.
Investigational New Drugs|October 1, 2013
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD studyM Martin-Richard, R Gallego, C Pericay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trialU B Patel, G Brown, I Machado, et al.
Pageof 4